Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Articles
Articles
Shedding Tiers for Better Value
Value Propositions
,
Value Peer-spectives
November/December 2010, Vol 1, No 6
Read More
Blood-Use Program Injects Clinical, Fiscal Control
Value Propositions
,
Value Peer-spectives
November/December 2010, Vol 1, No 6
A blood-use protocol program at Loyola University Hospital in Chicago has lowered the amount of blood products transfused per patient, which in turn has led to greater patient safety and lowered costs, according to research presented at the College of American Pathologists annual meeting in Chicago.
Read More
Free Is Good, Not Great, When It Comes to Screening
Value Propositions
,
Value Peer-spectives
November/December 2010, Vol 1, No 6
Removing payment for health insurance deductibles leads to increased, although modest, improvements in the rates of screening for conditions such as cancer and elevated cholesterol (Meeker D, et al. Health Serv Res. 2010. Online doi:10.1111/j.1475-6773.2010.01188.x).
Read More
CT Screening Shows Dramatic Benefit in Lung Cancer
Value Propositions
,
Value Peer-spectives
November/December 2010, Vol 1, No 6
A study comparing the use of computed tomography (CT) versus standard chest x-rays for screening those at high risk for lung cancer found that CT screening resulted in 20% fewer deaths from the disease.
Read More
Colorectal Cancer Screening: Spend Now to Save Later
Value Propositions
,
Value Peer-spectives
November/December 2010, Vol 1, No 6
Spending money on colorectal cancer screening programs that target the pre-Medicare population (those between 50 and 64 years of age) is necessary to reduce the costs of colorectal cancer in the Medicare program, according to research presented at the American College of Gastroenterology’s 75th Annual Scientific Meeting in San Antonio, TX.
Read More
Researchers Bark Up New Tree to Manufacture Cancer Drug
Value Propositions
,
Value Peer-spectives
November/December 2010, Vol 1, No 6
Paclitaxel (Taxol), which is produced from the bark of the yew, may become cheaper and easier to produce now that researchers have isolated and grown stem cells from that tree (Nat Biotechnol.
Read More
Filling in Funds Around NICE Gaps
Value Propositions
,
Value Peer-spectives
November/December 2010, Vol 1, No 6
The United Kingdom’s (UK) Department of Health has pledged £250 million toward a Cancer Drugs Fund that will pay for new treatments not available in the state-funded health system.
Read More
Price-Cutting May Spur Canadian Use of Cervical Vaccine
Value Propositions
,
Value Peer-spectives
November/December 2010, Vol 1, No 6
Read More
Bortezomib Bests Vincristine as Induction Therapy for MM
Cancer Quick Takes
November/December 2010, Vol 1, No 6
This study compared the safety and efficacy of a new regimen—bortezomib plus dexamethasone and vincristine— compared with vincristine (Oncovin), doxorubicin (Adriamycin), and dexamethasone (VAD) in previously untreated multiple myeloma (MM) (J Clin Oncol. 2010;28:4621-4629).
Read More
AML Trials: Phases and Changes
Cancer Quick Takes
November/December 2010, Vol 1, No 6
A discussion of new drug development using the example of acute myeloid leukemia (AML)—but that is applicable to a broad range of diseases— outlines the problems inherent in phase 2 clinical trials that may lead to falsepositive results, and how trial design can be improved and drug development be made more efficient and less costly (Blood. 2010;116:2420-2428).
Read More
Page 319 of 329
316
317
318
319
320
321
322
Top Trending Articles
1.
Immunotherapy Helps Navy Veteran Beat Stage 4 Lung Cancer
2.
HOPA Highlights: What's New in 2025?
3.
AUGTYRO (Repotrectinib) for the Treatment of ROS1-Positive Non-Small Cell Lung Cancer
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma